Novavax’s COVID-19 vaccine Nuvaxovid arrived in Singapore
On May 6, 2022, Novavax announced that deliveries of it’s COVID-19 vaccine continued around the world and the…
WHO reported Ebola virus disease in Democratic Republic of the Congo
On Apr. 28, 2022, the Ministry of Health of the Democratic Republic of the Congo declared an outbreak…
Human Avian H3N8 infection confirmed in Henan province
On Apr. 26, 2022, China’s National Health Commission reported a case of human infection with H3N8 avian influenza…
Cocrystal Pharma collaborated with the NIAID to evaluate COVID-19 protease inhibitors
On Apr. 21, 2022, Cocrystal Pharma announced a Non-Clinical Evaluation Agreement with the National Institute of Allergy and…
Novavax announced approval of Nuvaxovid COVID-19 vaccine for primary and booster immunization in Japan
On Apr. 19, 2022, Novavax announced that its partner, Takeda, received manufacturing and marketing approval from the Japan…
Swissmedic granted conditional Marketing Authorization for Novavax COVID-19 vaccine
On Apr. 13, 2022, Novavax announced that Swissmedic had granted Novavax conditional marketing authorization (CMA) for Nuvaxovid COVID-19…
Biotechnology | Diagnostics | Life Science News | Non-Profit Research | Oncology | Radiology | Therapeutics | Women's Health
Fred Hutch and Seattle Cancer Care Alliance unite, reshaped relationship with UW Medicine
On Apr. 1, 2022, the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance (SCCA) announced a…
Merck and Ridgeback reported data demonstrating treatment with LAGEVRIO (molnupiravir) associated with more rapid elimination of SARS-CoV-2 than placebo
On Apr. 1, 2022, Merck and Ridgeback Biotherapeutics announced that data evaluating LAGEVRIO(molnupiravir), an investigational oral antiviral COVID-19…
Sorrento reported FDA clearance for phase 2/3 study for Abivertinib in treatment of pospitalized patients with severe pneumonia due to COVID-19
On Mar. 31, 2022, Sorrento Therapeutics announced that the FDA had given clearance to commence the Phase 3…
Lucira’s COVID-19 & flu at-home molecular test showed Positive clinical trial results
On Mar. 30, 2022, Lucira Health announced that preliminary clinical trial results for its candidate COVID-19 & Flu…
Pfizer and BioNTech received expanded U.S. EUA for additional COVID-19 vaccine booster in individuals Aged 50 Years and older
On Mar. 29, 2022, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) had expanded…
Researchers generated the first complete, gapless sequence of a human genome
On Mar. 21, 2022, in support of the Cancer Moonshot goal of fostering data sharing in cancer research,…
Johnson & Johnson announced acquisition of Tibotec-Virco NV for $320 million in cash and debt
On Mar. 18, 2002, Johnson & Johnson announced an agreement to acquire all of the assets of Tibotec-Virco…
Genomics | NIH | Therapeutics
NIHï¾’s All of Us Research program released first genomic dataset of nearly 100,000 whole genome sequences
On Mar. 17, 2022, the National Institutes of Health announced that nearly 100,000 highly diverse whole genome sequences…
Soligenix COVID-19 vaccine, CiVax, boosted neutralizing activity against SARS-CoV-2, including Delta and Omicron
On Mar. 17, 2022, Soligenix announced the results of a booster vaccination study using CiVax (heat stable COVID-19…
Cocrystal Pharma initiated enrollment in phase 1 influenza a study with novel, broad-spectrum, orally administrated antiviral CC-42344
On Mar. 10, 2022, Cocrystal Pharma announced dosing of the first subjects in a Phase 1 clinical trial…
IHME reported three times as many deaths worldwide due to COVID-19 than official reports suggested
On Mar. 10, 2022, the Institute for Health Metrics and Evaluation (IHME) reported that more than three times…
Sorrento announced FDA authorization to proceed with phase 1 study of Intranasal STI-9199 against Covid-19 viruses
On Mar. 2, 2022, Sorrento Therapeutics announced that it had received clearance from the FDA for its investigational…
Medicago and GSK announced approval by Health Canada of COVIFENZ, an adjuvanted plant-based COVID-19 vaccine
On Feb. 24, 2022, Medicago and GlaxoSmithKline announced that Health Canada had granted approval for COVIFENZ, COVID-19 vaccine,…
Sorrento announced COVISHIELD antibody strongly neutralized BA.2 Omicron sublineage virus
On Feb. 22, 2022, Sorrento Therapeutics announced that additional preclinical results demonstrate broad spectrum COVISHIELD (STI-9167) neutralizing activity…
The University of Virginia Cancer Center Received NCI Comprehensive Designation
On Feb. 1, 2022, University of Virginia Cancer Center announced it had been awarded a Comprehensive Cancer Center…
Researchers documented third known case of HIV remission involving stem cell transplant
On Feb. 15, 2022, a woman with HIV who received a cord blood stem cell transplant to treat…
Gilead reported phase 2/3 interim data evaluating safety, tolerability and clinical outcomes of Veklury (Remdesivir) in pediatric patients with COVID-19
On Feb. 11, 2022, Gilead Sciences announced new data from an interim analysis of its ongoing, Phase 2/3…
Veklury (Remdesivir) retained antiviral activity against Omicron, Delta and other emergent SARS-CoV-2 variants
On Feb. 11, 2022, Gilead Sciences announced new data from an interim analysis of its ongoing, Phase 2/3…
Merck and Ridgeback announced 3.1 million courses of molnupiravir investigational oral antiviral COVID-19 medicine supplied to U.S. Government
On Feb. 8, 2022, Merck and Ridgeback Biotherapeutics announced that a total of 3.1 million courses of molnupiravir,…
NIAID Pandemic Preparedness Plan targeted ‘prototype’ and priority pathogens
On Feb. 2, 2022, NIAID scientists announced the new Pandemic Preparedness Plan aimed to support critical basic and…
Study of Penn patients with decade-long leukemia remissions after CAR T cell therapy revealed new details about persistence of personalized ‘Living Drug’ cells
On Feb. 2, 2022, a new analysis of the first two patients treated in a clinical trial with…
Artificial Intelligence | Biotechnology | CRISPR | Genomics | Life Science History | Life Science News | Medicine | NIH | Non-Profit Research | Therapeutics | Vaccine
Cancer MoonShot program reignited
On Feb. 2, 2022, President Biden announced a reignition of the Cancer Moonshot, that highlighted new goals: to…
Merck and Ridgeback’s Molnupiravir, investigational antiviral COVID-19 medicine, demonstrated activity against Omicron variant
On Jan. 28, 2022, Merck and Ridgeback Biotherapeutics announced data from six preclinical studies demonstrating that molnupiravir, an…
Cocrystal Pharma selected two lead antiviral drug candidates for COVID-19 oral drug program
On Jan. 27, 2022, Cocrystal Pharma announced that it had selected two investigational novel antiviral drug candidates for…